We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Value of Left Atrial Appendage Flow for Prediction of Successful Catheter Ablation for Persistent Atrial Fibrillation (CLAAAF)

This study has been terminated.
(40 patients)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01144858
First Posted: June 16, 2010
Last Update Posted: June 16, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Clinique Pasteur
  Purpose
The purpose of this study was to determine whether left atrial appendage flow velocity, as determined using trans esophageal echocardiography (TEE), predicts the outcome after catheter ablation of persistent Atrial fibrillation( pAF).

Condition Intervention
Persistent Atrial Fibrillation Catheter Ablation Other: a complete transesophageal echocardiography

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Value of Left Atrial Appendage Flow for Prediction of Successful Catheter Ablation for Persistent Atrial Fibrillation

Resource links provided by NLM:


Further study details as provided by Clinique Pasteur:

Primary Outcome Measures:
  • termination of persistent AF by catheter ablation

Secondary Outcome Measures:
  • Recurrences of AF were therefore determined from holter monitoring at 3 and 6 months or 12 leads ECG in care of symptomatic palpitation with clinical interview.

Enrollment: 40
Study Start Date: January 2009
Study Completion Date: December 2009
Groups/Cohorts Assigned Interventions
patients with persistent atrial fibrillation ablation Other: a complete transesophageal echocardiography
All patients were evaluated by a complete transesophageal echocardiography with multiplane probes with a 7-MHz transducer before catheter ablation .LA appendage flow was obtained by placing the pulsed Doppler sample volume at the orifice of the LA appendage, after which peak flow velocities were measured and averaged within each RR interval of 10 consecutive cardiac cycles

Detailed Description:
40 PAF patients underwent 3D mapping and ablation. A stepwise approach including circumferential pulmonary vein (PV) isolation, continuous complex-fractionated electrogram (CFE) ablation and linear ablation was performed by the same operator. The procedural end point was termination of persistent AF by catheter ablation, either by conversion directly to sinus rhythm or to atrial tachycardia. Left atrial appendage (LAA) peak flow velocities were measured with transesophageal echography and averaged within each RR interval of 10 consecutive cardiac cycles.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
40 consecutive patients who underwent first-time radiofrequency catheter ablation for pAF. pAF was defined as continuous AF lasting longer than 1 month, resistant to either electrical or pharmacological cardioversion
Criteria

Inclusion Criteria:

  • First-time radiofrequency catheter ablation for pAF. pAF was defined as continuous AF lasting longer than 1 month, resistant to either electrical or pharmacological cardioversion.
  • Informed consent

Exclusion Criteria:

  • Severe valvular disease requiring surgery
  • Valvular prosthesis
  • Known severe coronary artery disease
  • Atrial and/or ventricular thrombosis
  • New York Heart Association functional class III to IV
  • Cerebrovascular disease
  • Pulmonary embolism
  • Latent or manifest hyperthyroidism
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01144858


Locations
France
Clinique Pasteur
Toulouse, 43-45 avenue de Lombez, France, 31076
Sponsors and Collaborators
Clinique Pasteur
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT01144858     History of Changes
Other Study ID Numbers: past-1001-ryth
First Submitted: June 15, 2010
First Posted: June 16, 2010
Last Update Posted: June 16, 2010
Last Verified: October 2008

Keywords provided by Clinique Pasteur:
atrial fibrillation
ablation catheter
left atrial appendage peak emptying velocity
tool for predicting successful catheter ablation

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes